about
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseDifferential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.Effects of cholesterol on the phenotype of rabbit bile duct fibroblastsTargeting Adenosine Receptors for the Treatment of Cardiac FibrosisThyroid Hormone Increases TGF-beta1 in Cardiomyocytes Cultures Independently of Angiotensin II Type 1 and Type 2 Receptors.Therapeutic potential of angiotensin II receptor antagonists.The renin-angiotensin-aldosterone system and vascular remodeling.An updated concept for left ventricular hypertrophy risk in hypertension.Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).Angiotensinogen gene transcription in pulmonary fibrosisCardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.Tomoregulin-1 prevents cardiac hypertrophy after pressure overload in mice by inhibiting TAK1-JNK pathways.Cardiac Fibrosis: The Fibroblast AwakensNew therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.Angiotensin II receptor blockers in the prevention of complications from atrial fibrillationFibrosis and heart failure.Surgical scar revision: an overview.Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetesModulation by bradykinin of angiotensin type 1 receptor-evoked RhoA activation of connective tissue growth factor expression in human lung fibroblasts.Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges.Cardiac biomarkers in children with congenital heart disease.The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarctionPathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation.Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle.Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4.The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4).Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel TargetPlasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta.Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy.Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression.Epac is required for exogenous and endogenous stimulation of adenosine A2B receptor for inhibition of angiotensin II-induced collagen synthesis and myofibroblast differentiation.Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts.
P2860
Q28077454-3D5E5ED1-5384-4379-8761-3F2AF99A9C74Q30483132-F6A8CAA5-5F4F-48C8-9A86-B73919EE2F50Q30881752-2E9BC20E-3F08-4409-A210-FAD89CC40A2FQ33639481-DFB4B919-DF29-4E89-84E0-B965238215ADQ33960840-4F23AB85-09CF-42D7-96F7-624A3E8C7B4EQ34481715-5481373F-FAB1-4493-8CC2-3FC5F663AB76Q34513169-CF3D1E39-3409-46C9-89DE-1BD7035043E8Q34986413-7B28E1B7-62CB-47A4-9218-14AF666EFF11Q35186659-DFE1BFD5-E519-4278-B16C-0978BBBC7333Q35829724-6B161170-1040-4A16-A74E-2A9DB9EC1033Q35921700-072F7ED2-B45E-423E-85CB-385A859E23CAQ35923510-B7A2CABD-4176-471F-8638-D6564AA793E2Q36708340-5662DA8D-70BD-43DE-B433-EEDE6E0203CCQ37043556-8ECCB998-720D-448A-A63D-A5C209F5A300Q37354665-FFA6876E-B335-4B08-A26F-FE3894AC2D16Q38057701-9D1E26FB-5F6F-4860-B8F3-B1118CD18BF0Q38206774-C534680F-0493-42CE-BE5C-D7527628E85EQ38281695-04AC848A-F4B6-4401-BAEA-E3CDE893A139Q38313477-235BE60C-E39D-4FAA-8BEF-3C8102531522Q38560476-5341133D-2E00-4B4C-8EF5-15F259EC1D6CQ38603770-D9B713D7-FCE6-4D2E-86B9-7BC0E1D9C7DCQ38705911-9B47B210-5215-41CD-B7F6-997A49491C7FQ38884029-BB11C895-38DE-4784-9FF9-2886761126C2Q39185363-08E6F7C7-8AC0-490B-AEC8-4DB8C387605EQ39613493-C625E57C-FDF0-48E7-A245-C2338624562BQ41832975-0CBA2875-7338-4C69-8533-0FE2F682A3E0Q42375617-58D41F6F-A336-4ABD-8AAB-8E76341D6EE1Q45868567-E5324902-90C0-4EC4-B629-6931F9D05B33Q46661981-18436B1E-AA8B-4FE3-9004-057670234131Q46967668-67AAEEA4-CFCD-44E4-84B5-F5A5B797B310Q47159762-4D2C019E-9255-4910-811E-17E1564854ADQ47225662-F0DB8D75-18FD-48DA-A755-B5BF1AC63E39Q48265051-CF0B602E-44F3-4C02-AEB0-60EDEFE7462BQ54597907-0B8EDD2E-8883-4B4C-893B-C3E032C3A755
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Angiotensin II, adhesion, and cardiac fibrosis.
@ast
Angiotensin II, adhesion, and cardiac fibrosis.
@en
type
label
Angiotensin II, adhesion, and cardiac fibrosis.
@ast
Angiotensin II, adhesion, and cardiac fibrosis.
@en
prefLabel
Angiotensin II, adhesion, and cardiac fibrosis.
@ast
Angiotensin II, adhesion, and cardiac fibrosis.
@en
P1476
Angiotensin II, adhesion, and cardiac fibrosis.
@en
P2093
P304
P356
10.1016/S0008-6363(00)00044-4
P577
2000-05-01T00:00:00Z